Nuvation Bio upgraded to Buy from Neutral at BTIG

BTIG upgraded Nuvation Bio (NUVB) to Buy from Neutral with a $5 price target. The company’s acquisition of AnHeart Therapeutics “looks promising” as it provides Nuvation two potentially best-in-class drugs, one of which, taletrectinib, is in pivotal trials and could receive approval as early as 2025, the analyst tells investors in a research note. The firm says data to date suggest that taletrectinib has a better drug profile than Bristol’s (BMY) repotrectinib in terms of both safety and efficacy. BTIG believes Nuvation might be able to launch taletrectinib in the U.S. as early as late 2025.